Vaxcyte to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

Vaxcyte (Nasdaq: PCVX) announced that management will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022. The presentation is set for 2:20 p.m. ET / 11:20 a.m. PT. A live webcast will be available on the company’s website, with a replay accessible for 30 days post-conference. Vaxcyte focuses on engineering high-fidelity vaccines to combat bacterial diseases, with its lead candidate, VAX-24, aimed at preventing invasive pneumococcal disease.

SAN CARLOS, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will present at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 2:20 p.m. ET / 11:20 a.m. PT.

A live webcast of the presentation can be accessed through the Investors & Media section of the Company’s website at http://investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference.

About Vaxcyte
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal disease. Vaxcyte is re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF^TM cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-XP, a PCV with an expanded breadth of coverage of greater than 30 strains; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked. For more information, visit www.vaxcyte.com.

Contacts:
Andrew Guggenhime, President and Chief Financial Officer
Vaxcyte, Inc.
650-837-0111
investors@vaxcyte.com

Janet Graesser, Vice President, Corporate Communications and Investor Relations
Vaxcyte, Inc.
917-685-8799
media@vaxcyte.com 

FAQ

When will Vaxcyte present at the SVB Leerink Global Healthcare Conference?

Vaxcyte will present on February 18, 2022, at 2:20 p.m. ET.

How can I access the Vaxcyte conference presentation?

The presentation will be accessible via a live webcast on Vaxcyte's Investors & Media section of their website.

What is the ticker symbol for Vaxcyte?

The ticker symbol for Vaxcyte is PCVX.

What is Vaxcyte's lead vaccine candidate?

Vaxcyte's lead vaccine candidate is VAX-24, designed to prevent invasive pneumococcal disease.

How long will the webcast replay be available after the conference?

The webcast replay will be available for approximately 30 days following the conference.